BRIEFAbbvie says investigational IL23 inhibitor Risankizumab receives Orphan Drug Designation from U.S. FDA

Abbvie receives Orphan Drug Designation forinvestigational IL23 inhibitor Risankizumab from the U.S. Foodand Drug Administration for the treatment of pediatric patientswith Crohn's DiseaseSource text for Eikon Further company coverage